Warner-Lambert-Pfizer

Before the merger of Pfizer and Warner-Lambert Co., Parke Davis, a division of Warner-Lambert, distributed Neurontin. PDR. at 2459. We refer to Pfizer Warner-Lambert (Pfizer) throughout, but some of the activity discussed was carried out by its predecessor Warner-Lambert. 

The pharmaceutical industry in industrialized countries experienced a high rate of merger and acquisition activity in the 1980s and 1990s. Most of the leading pharmaceutical firms in the OECD countries are the result of one or more horizontal mergers. For example, Pfizer is the combination of Pfizer, Warner-Lambert, and Pharmacia, which included Upjohn (Danzon, Epstein, and Nicholson 2003). 

Sometimes, the choice of comparator can backfire badly. Zocor Merck s Statin was run by Merck against Pfizer/Warner Lambert s Lipitor in another billion dollar study, and it was proven less effective. Merck made a huge favor to Pfizer that paid dearly but astutely to acquire Lipitor for its cardiovascular franchise. 

Otosporia (Warner-Lambert)-comb. Polymyxin B sulfate (Pfizer)... 

Pfizer introduced troglitazone in 1997 and marketed it as Rezulin, an oral treatment for type 2 diabetes. Warner Lambert Co., which was acquired by Pfizer in June 2000, discontinued marketing this drug in March 2000. In January 2003, the company... 

Quinapril (3, CI-906), marketed by Pfizer under the trade name Accupril , was discovered at Warner-Lambert (Klutchko et al., 1986). Like enalapril, quinapril is a prodrug, and is... 

Pfizer, the current owner of Warner-Lambert, has faced numerous lawsuits over Rezulin. By 2003, the number of suits reached 8,700, and another... 

Pfizer merges with Warner-Lambert and gains the rights to the highly successful anticholesterol statin drug Lipitor. 

March 3 In Warner-Lambert v. Kimberly Kent, the Supreme Court affirms a lower court decision allowing a Michigan class-action suit to proceed against Pfizer over the diabetes drug Rezulin. 

Within the pharmaceutical industry itself, the wish of each company s management to see its firm reach what is considered a critical size remained a constant feature as the century came to an end and the new millennium began. It led to new national and transnational mergers. In France, Sanofi (Elf Aquitaine) merged with Synthelabo (L Oreal) and Laboratoires Pierre Fabre with BioMerieux. Elsewhere the Swedish Astra and the British Zeneca combined their operations Pharmacia-Upjohn took control of Monsanto and two giant firms, Glaxo Wellcome and SmithKline Beecham, announced their intention to combine their activities, which would lead to a group with a turnover of 25 billion, exceeded only by Pfizer after its acquisition of Warner Lambert. 

The stock plunged from nearly 100 at the end of 2000 to the 40s in the summer and early fall of 2002. Merck unexpectedly announced in June 2001 that it would miss its earnings for that year, then followed up in December with the shocker that its earnings for the next year would be flat. On Wall Street, the pressure grew to seek a merger, even as archrival Pfizer swallowed up Warner-Lambert Company, then Pharmacia. 

Presumably, too, mergers save money, through layoffs and economies of scale, that can then be used for more research. You fire the blue-collar people, close plants, it buys you two years, maybe three, sums up Evans, the Sanford Bernstein analyst. Pfizer expected to book 270 million in savings from its acquisition of Warner-Lambert and a further 2.5 billion from Pharmacia. Even before the Pharmacia deal, its R D budget was almost double Merck s with Pharmacia, it would be spending over 7 billion, versus less than 3 billion for Merck. Standing alone, Merck didn t have a prayer of coming close. 

There has been and will continue to be iimovative reconstruction of the pharmaceutical industry with, for example, cross-licensing of products and expertise. Sandoz collaborated with Bristol Myers Squibb (BMS) in oncology. Other companies have a more acquisitive outlook. Pfizer bought Warner-Lambert for its cholesterol-lowering Lipitor, and Pharmacia merged with UpJohn-Searle for its COX-2 inhibitor. Pfizer then acquired Pharmacia-UpJohn-Searle to become the world s largest pharmaceutical company. 

The product troglitazone was a melt-extruded product that was scaled up and launched by Warner-Lambert (Pfizer) Co. A schematic of the manufacturing unit operation is shown in Fig. 16. The scale-up steps... 

Pharmacia and Upjohn AstraZeneca Warner Lambert Pfizer Glaxo Wellcome American Home Products Bristol-Myers Squibb Abbott Merck... 

---